Dapakem 10
Dapakem 10 - Image 3
,

Dapakem 10

Composition:

  • Dapagliflozin 10 mg
    Therapeutic Class:

  • SGLT2 Inhibitor (Sodium-Glucose Co-Transporter 2 Inhibitor)
    Schedule: Schedule H (Rx Only)

Dapakem 10 contains Dapagliflozin, a selective SGLT2 inhibitor that offers glycemic control, cardiovascular protection, and renal benefits in patients with type 2 diabetes mellitus (T2DM). By promoting glucose excretion through urine, it reduces blood sugar independently of insulin, making it a valuable add-on or monotherapy option.

Dapagliflozin is also increasingly used in heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) for its cardio-renal protective effects.

Usage of Dapakem 10

Dapakem 10 is indicated for:

  • Type 2 Diabetes Mellitus (T2DM) – as monotherapy or in combination

  • Heart Failure with Reduced Ejection Fraction (HFrEF) – even in non-diabetics

  • Chronic Kidney Disease (CKD) – to slow progression and reduce hospitalization

  • Obese or overweight diabetic patients – supports weight loss and BP control

Mechanism of Action

  • Blocks SGLT2 in the proximal renal tubules → prevents glucose reabsorption

  • Promotes urinary glucose excretion → lowers plasma glucose

  • Mild osmotic diuresis and natriuresis → reduces preload and BP

  • Improves cardiovascular outcomes via multiple mechanisms (hemodynamic, metabolic, renal)

Key Benefits

✅ Reduces HbA1c by 0.5–1%
✅ Promotes weight loss (2–3 kg)
✅ Lowers systolic BP (~4–6 mmHg)
✅ Cardio-renal protection in HF and CKD patients
✅ Low risk of hypoglycemia when used alone

Common Side Effects

  • Increased urination

  • Genital mycotic infections (e.g., candidiasis)

  • Urinary tract infections

  • Dehydration, hypotension (esp. in elderly)

  • Rare: Diabetic ketoacidosis (even with normal blood sugar – euglycemic DKA)

Precautions

  • Not recommended in Type 1 diabetes mellitus

  • Avoid in patients with eGFR < 30 mL/min/1.73 m²

  • Caution in elderly and volume-depleted patients

  • Monitor for DKA symptoms: nausea, vomiting, abdominal pain, breathlessness

  • Not advised during pregnancy or lactation

Drug Interactions

  • May enhance effects of diuretics → risk of dehydration

  • Increased risk of hypoglycemia when used with insulin or sulfonylureas

  • No major CYP interactions; minimal hepatic metabolism

Dosage & Administration

  • Usual dose: 10 mg once daily, with or without food

  • Renal Dose Adjustments:

    • eGFR ≥ 45: Use with monitoring

    • eGFR < 30: Not recommended for glycemic control

  • Can be used as monotherapy or add-on to metformin, DPP-4 inhibitors, sulfonylureas, insulin

Storage

  • Store below 25°C

  • Keep away from moisture and sunlight

  • Protect from children

Patient Counseling Points

  • Maintain good genital hygiene to prevent infections

  • Stay hydrated, especially during hot weather

  • Report signs of UTIs or genital irritation promptly

  • Do not skip meals even if blood sugar improves

  • Inform doctor if experiencing abdominal pain, deep breathing, or fatigue (signs of DKA)

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout